Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Peter Clark, MA, MD, FRCP: A Payer Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Apr
10
Today In Oncology
How Cannabis Use May Be Accelerating Breast and Testicular Cancer Rates in AYAs
Japanese Study Looks at Rates of Cancer Therapy–Related AML
Researchers Identify Blood-Based Biomarker for Cancer Risk in People With Lynch Syndrome
Final Report on Pralsetinib in Advanced RET Fusion–Positive NSCLC
New ASH HematOmics Program Offers Blood Cancer Data Integration Tool to Accelerate Research
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo